In an extensive KRAS mutation analysis using PCR amplification of DNA samples isolated from supernatant (cell-free) and cells from ascites fluid as well as primary tumor tissues, Yamashita and colleagues detected KRAS point mutations in 8 out of 9 ascites supernatant samples from patients with pancreatic cancer including 2 cases of negative cytologic diagnosis (34). This evidence concerns the gene KRAS and pancreatic neoplasm.